12,52 $
5,08 %heute
Nasdaq, 29. Februar, 18:50 Uhr
ISIN
US67080M1036
Symbol
NRIX
Berichte
Sektor
Industrie

Nurix Therapeutics Inc Aktie News

Neutral
GlobeNewsWire
14 Tage alt
NX-5948 received Fast Track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK-4 for rheumatoid arthritis Formed strategic collaboration with Seagen (now Pfizer) to advance a portfolio of degrader-antibody co...
Neutral
GlobeNewsWire
28 Tage alt
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127
Positiv
Seeking Alpha
etwa ein Monat alt
Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies. Protein degradation platform offers several advantages over other BTK drugs, such as ability to overcome mutation resistance and complete removal of BTK scaffolding. The global Bruton Tyrosine Kinase [BTK] inhibitors market is expected to rea...
Neutral
GlobeNewsWire
etwa ein Monat alt
Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Hodgkin lymphoma indications Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Hodgkin lymphoma indicat...
Neutral
GlobeNewsWire
etwa 2 Monate alt
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix's achieveme...
Neutral
GlobeNewsWire
3 Monate alt
Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL)
Neutral
GlobeNewsWire
3 Monate alt
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton's tyrosine kinase (BTK) ...
Neutral
GlobeNewsWire
4 Monate alt
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that clinical data will be presented for its two BTK degrader programs, NX-5948 and NX-2127, in two posters at the 65th American...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen